Welcome to our dedicated page for Immunome SEC filings (Ticker: IMNM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Immunome, Inc. (IMNM) SEC filings page on Stock Titan provides direct access to the company’s U.S. Securities and Exchange Commission disclosures, including Form 8-K current reports and other registered offerings. These documents are central for understanding how a clinical-stage targeted oncology company like Immunome describes its pipeline, clinical data and capital raising activities to regulators and investors.
Immunome’s recent Form 8-K filings cover several important topics. One 8-K details positive topline results from the global pivotal Phase 3 RINGSIDE trial of varegacestat, the company’s investigational oral gamma secretase inhibitor for progressing desmoid tumors, including the primary endpoint in progression-free survival and key secondary endpoints. The same filing discusses safety findings and the company’s stated plan to submit a New Drug Application for varegacestat to the U.S. Food and Drug Administration.
Other 8-Ks address financial and capital markets events, such as a follow-on public offering of common stock under an effective shelf registration statement on Form S-3, including the number of shares, public offering price and underwriters. Additional current reports reference quarterly financial results, business updates, and the furnishing of investor presentations that describe Immunome’s pipeline, including IM-1021, IM-3050 and preclinical ADC programs built around the HC74 TOP1 inhibitor payload.
Through this page, users can review how Immunome characterizes the design and potential attributes of its HC74 payload, summarizes preclinical data, and outlines risks and forward-looking statements in its regulatory language. Stock Titan enhances access to these filings with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly identify clinical milestones, financing terms, and strategic disclosures without manually parsing every section.